Applied Biosciences Corp. (APPB)
| Market Cap | 2.14K -99.9% |
| Revenue (ttm) | 859.86K +75.3% |
| Net Income | -2.79M |
| EPS | -0.20 |
| Shares Out | 21.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Average Volume | 6,401 |
| Open | 0.0001 |
| Previous Close | n/a |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.000001 - 0.0001 |
| Beta | 2,346.10 |
| RSI | 47.39 |
| Earnings Date | n/a |
About Applied Biosciences
Applied Biosciences Corp. focuses on the development and commercialization of synthetic cannabinoid therapeutics/biopharmaceuticals that target the endocannabinoid system to treat a range of diseases across various therapeutic areas. It delivers consumer and OTC THC-free CBD products that promote overall health and wellbeing, as well as testing and analytics capabilities to its customers. The company was incorporated in 2014 and is based in Beverly Hills, California. [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2019, Applied Biosciences's revenue was $707,062, an increase of 257.91% compared to the previous year's $197,554. Losses were -$2.63 million, 10.7% more than in 2018.
Financial StatementsNews
U.S. SEC charges two companies, CEO over misleading COVID-19 claims
The U.S. Securities and Exchange Commission said on Thursday it has charged two companies and a chief executive officer with making misleading claims related to COVID-19, the disease caused by the nov...